SCHEMBL14927388

SCHEMBL14927388

CCCn1c(=O)n(Cc2ccccc2)c(=O)c2cc(C)ccc21

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.56
▸ KMT2A Q03164 2/20 0.55
▸ LMNA P02545 1/20 0.55
▸ PGR P06401 1/20 0.54
▸ RORA P35398 1/20 0.54
▸ RORC P51449 1/20 0.54
▸ RORB Q92753 1/20 0.54
▸ POLB P06746 1/20 0.52
▸ DHFR P00374 1/20 0.51
▸ MAPT P10636 4/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ MIF P14174 1/20 0.49
▸ HDAC1 Q13547 1/20 0.47
▸ HDAC11 Q96DB2 1/20 0.47
▸ HDAC8 Q9BY41 1/20 0.47
▸ HDAC6 Q9UBN7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14927365 0.92 PGR (0.50) TP53KMT2ALMNAPGRRORA
SCHEMBL10085035 0.88 KDM4E (0.48) TP53KMT2APGRRORARORC
SCHEMBL10084697 0.86 PGR (0.57) PGRRORARORCRORBPOLB
SCHEMBL14927363 0.85 PDE1A (0.54) TP53MAPTHDAC1HDAC11HDAC8
SCHEMBL10084721 0.85 TP53 (0.63) TP53KMT2ALMNAPOLBDHFR
SCHEMBL14927379 0.84 TP53 (0.53) TP53PGRRORARORCRORB
SCHEMBL14927481 0.81 PGR (0.47) KMT2ALMNAPGRRORARORC
SCHEMBL14927487 0.80 RORA (0.46) TP53PGRRORARORCRORB
SCHEMBL14927441 0.80 PGR (0.49) TP53KMT2ALMNAPGRRORA
SCHEMBL679026 0.77 KMT2A (0.64) TP53KMT2ALMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9732078-B2 Therapeutic use of imidazopyridine derivatives SANOFI (FR) 2017-08-15 — — US disclosed
US-9452164-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2016-09-27 — — US disclosed
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives SANOFI (FR) 2014-11-20 — — US disclosed
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-28 — — US disclosed
US-8759344-B2 Imidazopyridine derivatives, process for preparation thereof and therapeutic use thereof SANOFI (FR) 2014-06-24 — — US disclosed
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243328-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH TP53 1684/4885KMT2A 1185/4885LMNA 911/4885
US-20140343054-A1 Therapeutic Use of Imidazopyridine Derivatives CCNY, UTS2R, WNK2 TP53 158/4885KMT2A 847/4885LMNA 2164/4885
US-20130116250-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, ENY2, PAH TP53 1684/4885KMT2A 1185/4885LMNA 911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback